Private Equity in Veterinary 2026: Active Platforms, Multiples, and Consolidation

TL;DR: The US veterinary services market reached $36.52B in 2024 and is projected to hit $68.67B by 2033 (Grand View Research). Private-equity and corporate ownership has expanded from roughly 8% of U.S. clinics in 2011 to approximately 50% by 2025, with independent practices still holding about 51% of sites. Verified active 2026 buyers include Mars Veterinary Health (private CPG conglomerate, ~3,000 global hospitals via Banfield, VCA, BluePearl), Ethos Veterinary Health (formerly JAB Holding portfolio; acquired NVA July 31, 2025), PetVet Care Centers (KKR; $2.3B unitranche recap 2023), Thrive Pet Healthcare (TSG Consumer Partners; distressed per S&P CCC+ April 2025), Mission Pet Health (Southern Veterinary Partners + Mission Veterinary Partners merged 2025), Heartland Veterinary Partners, and VetCor (Harvest Partners + Cressey & Company). Multiples: 5x-7x EBITDA for small practices, 8x-11.5x EBITDA for $1M-$3M EBITDA practices, 11x-13x+ for platform-eligible operators ($3M+ EBITDA). Important regulatory context: the FTC has taken multiple actions against JAB requiring divestitures, signaling active antitrust scrutiny of vet roll-ups. CT Acquisitions is buy-side. Every named platform, sponsor, and multiple on this page is sourced to a primary press release, FTC filing, SEC filing, or sponsor portfolio page.

Methodology and data sources

This tracker follows CT Acquisitions’ 5-tier source hierarchy for research-grade content:

1. Tier 1 — Press releases from sponsors, platforms, and their advisors (PR Newswire, GlobeNewswire, sponsor.com/news, platform.com/news)
2. Tier 2 — SEC filings and FTC orders (VCA’s 2017 8-K, FTC Matter 2110140 against JAB Consumer Partners)
3. Tier 3 — Sponsor portfolio pages (current portfolio status, not historical)
4. Tier 4 — Trade press (Veterinary Practice News, dvm360, Today’s Veterinary Business, AVMA News)
5. Tier 5 — M&A trade press (PE Hub, PE Professional, Mansfield Advisors, Ackerman Group)

Industry-data tier (multiples, market size, fragmentation): IBISWorld (NAICS 541940 Veterinary Services), Mordor Intelligence, Grand View Research, First Page Sage, Peak Business Valuation, SovDoc, Transitions Elite, AVMA Veterinary Industry Tracker.

Verification window: All platform sponsors and scale figures verified May 2026. The vet space has had multiple structural changes through 2025 (NVA acquired by Ethos, SVP + Mission merger, JAB divestitures); see “Future Updates” for the quarterly refresh cadence.

Inclusion criteria for “active platform”: (a) a verifiable current institutional sponsor, corporate parent, or publicly traded ultimate parent; (b) at least 25 U.S. veterinary hospital or clinic locations; and (c) at least one verified add-on acquisition in the last 24 months or a stated active-acquirer posture.

The 2026 veterinary PE landscape: why now

Four structural forces explain the durability of capital in vet consolidation through 2026:

• Recurring patient demand. Pet ownership grew sharply through 2020-2022, the installed base of companion animals is at all-time highs, and vet visit frequency for wellness, dental, and chronic-disease management creates structural recurring revenue.
• Fragmentation runway. Despite consolidation, independent clinics still hold approximately 51% of sites (Mordor Intelligence). PE-backed and corporate share has grown from ~8% in 2011 to ~50% in 2025; the remaining independent half is the runway. Source: Mordor Intelligence veterinary services market report.
• High-margin specialty and ER expansion. Specialty and emergency veterinary care commands materially higher multiples than general practice because of higher case acuity, lower price-shopping, and 24/7 utilization patterns. This is the explicit M&A thesis behind Ethos and BluePearl.
• Regulatory scrutiny has not stopped consolidation. The FTC has imposed divestitures and prior-approval requirements on JAB Consumer Partners in both the Ethos and SAGE acquisitions, but has not blocked the underlying consolidation thesis. Sources: FTC second action against JAB (2022) | AVMA on FTC actions.

The result: Mars Veterinary Health alone operates nearly 3,000 vet hospitals worldwide (Banfield + VCA + BluePearl + AniCura + Linnaeus), and at least 6 institutional platforms are actively buying in 2026.

Active platforms: profiles of 7 veterinary operators

Apex tier (national platforms, 400+ locations)

Mars Veterinary Health — Ownership: private CPG conglomerate (NOT PE). Brand family: Banfield Pet Hospital (1,000+ U.S. general practices), VCA Animal Hospitals (1,000+ U.S./Canadian locations), BluePearl Specialty and Emergency Pet Hospital (advanced referral hospitals across 29 U.S. states), plus AniCura and Linnaeus in Europe. Total: approximately 3,000 hospitals worldwide. The $9.1B acquisition of VCA in 2017 (closed September 2017) remains the largest single transaction in veterinary services history. The FTC required Mars to divest 12 specialty / off-hours emergency hospitals as a condition of closing. Sources: PR Newswire: Mars completes VCA acquisition | VCA press center on Mars acquisition | Veterinary Practice News on close | Fortune: Mars as the biggest vet provider.

Ethos Veterinary Health — Sponsor: JAB Holding Company (JAB Consumer Partners). Important 2025 status change: On July 31, 2025, Ethos Veterinary Health acquired NVA (National Veterinary Associates) from JAB. The combined platform is in active restructuring after JAB’s 2024 announcement that it would split its pet healthcare business into two distinct entities (NVA general practice and Ethos specialty) to prepare for separate IPOs. As of pre-acquisition, Ethos managed 145 specialty veterinary hospitals (legacy Ethos + Compassion-First + Sage + legacy NVA specialty) and NVA partnered with 700+ general/specialty/ER hospitals globally. FTC context: As a condition of JAB’s $1.65B acquisition of Ethos in 2022, the FTC ordered divestitures in Richmond, Denver, San Francisco, and D.C. metro markets; the SAGE transaction required 11 separate clinic divestitures. Sources: Ethos: NVA and Ethos announcement | PE Hub: JAB / NVA buys Ethos $1.65B | AVMA: NVA splits into two businesses | FTC Matter 2110140: JAB / NVA / SAGE.

PetVet Care Centers — Sponsor: KKR (since 2017, acquired from L Catterton + Ontario Teachers’ Pension Plan). Scale: 450+ veterinary clinics and hospitals across the U.S. Important 2023 transaction: KKR completed a $2.3B unitranche recapitalization led by Blue Owl Capital, with Ares Management, Oaktree Capital, and Oak Hill Advisors participating, plus $400M of preferred equity from third-party investors and $600M of additional common equity from KKR. Proceeds used to repay over $3B of outstanding debt that matured starting in 2025. Source: L Catterton press: KKR acquires PetVet | Today’s Veterinary Business on the KKR / PetVet recapitalization (referenced via PE Hub coverage).

Growth tier (100-400 locations)

Mission Pet Health — Newly formed 2025. The merger of Southern Veterinary Partners (multiple PE sponsors historically including Shore Capital Partners) and Mission Veterinary Partners (Shore Capital Partners) closed in late 2024 and rebranded as Mission Pet Health on August 4, 2025. The combined entity is one of the largest non-Mars / non-JAB platforms in U.S. veterinary services. Source: GlobeNewswire: SVP + MVP merger announcement | Mission Pet Health: merger announcement.

Thrive Pet Healthcare (formerly Pathway Vet Alliance) — Sponsor: TSG Consumer Partners (majority since 2020, acquired from Morgan Stanley Capital Partners). Scale: 400+ veterinary hospitals across the US. Important 2025 status: Thrive is in active financial distress. S&P downgraded the issuer to CCC+ in April 2025 on negative cash flow and high leverage, and the company completed a large-scale liability management exercise in March 2025 that extended maturities by one year (to 2028) and increased liquidity. S&P described the capital structure as “likely unsustainable.” Owners considering an exit should weigh Thrive’s near-term capacity to close acquisitions against its distress status. Source: TSG Consumer portfolio page and S&P credit research (referenced via Octus / ION Analytics).

VetCor — Sponsors: Harvest Partners + Cressey & Company. Scale: National network of veterinary hospitals; aggressive acquisition cadence reported across 2024-2025 (more than 20 acquisitions in a 6-month period per industry reporting). The platform’s stated thesis emphasizes practice autonomy and culture preservation. Source: VetCor company site.

Mid-market / regional tier

Heartland Veterinary Partners — Sponsor: institutional PE-backed (per company materials and trade press). Scale: regional network in the Midwest and South. Stated thesis is operational support (payroll, HR, marketing) to vet partners. Source: Heartland Veterinary Partners company site.

Acquisition velocity: what 2024-2026 tells us

Disclosed major veterinary equity events 2017-2026:

• January 2017 — Mars enters agreement to acquire VCA for $93/share ($9.1B all-cash including $1.4B debt; approximately 41% premium to 30-day VWAP). Source: VCA Form 8-K (Jan 9, 2017).
• September 12, 2017 — Mars completes the VCA acquisition. FTC required divestiture of 12 specialty / off-hours emergency animal hospitals from the combined 1,900+ U.S./Canada locations. Source: PR Newswire (link above).
• 2017 — KKR acquires PetVet Care Centers from L Catterton and Ontario Teachers’ Pension Plan.
• 2019 — JAB Holding acquires NVA.
• 2020 — TSG Consumer Partners acquires majority of Pathway Vet Alliance (later Thrive Pet Healthcare) from Morgan Stanley Capital Partners.
• June 2022 — FTC takes second action against JAB Consumer Partners. JAB’s $1.65B acquisition of Ethos required divestitures in Richmond, Denver, San Francisco, and D.C. metro. Source: FTC second action announcement (June 2022).
• October 2023 — KKR closes $2.3B unitranche recapitalization of PetVet led by Blue Owl, Ares, Oaktree, and Oak Hill Advisors. KKR adds $600M of common equity; third-party preferred adds $400M.
• 2024 — JAB announces NVA / Ethos split into two distinct businesses, preparing for separate IPOs. Source: AVMA / Today’s Veterinary Business.
• Late 2024 — Southern Veterinary Partners and Mission Veterinary Partners agree to merge.
• March 2025 — Thrive Pet Healthcare completes large-scale liability management; extends maturities to 2028.
• April 2025 — S&P downgrades Thrive to CCC+; describes capital structure as “likely unsustainable.”
• July 21, 2025 — SVP + MVP merger announcement; combined entity rebranded as Mission Pet Health effective August 4, 2025.
• July 31, 2025 — Ethos Veterinary Health acquires NVA from JAB. Per the prior FTC order, JAB was required to divest clinics in Richmond, Denver, San Francisco, and D.C. metro. Source: Ethos announcement.

Note on private equity disclosure norms: Most platform-level vet transactions do not disclose enterprise value, EBITDA, or multiples. Where press accounts cite a number (e.g., JAB $1.65B for Ethos, Mars $9.1B for VCA), we attribute it to the reporter or to a public SEC filing. Where multiples are quoted as ranges they reflect industry-data tier sources, not specific transactions.

Multiples and deal structure: what veterinary owners should expect

Veterinary valuation has compressed upward materially since the pre-2018 era when 5x-6x EBITDA was the prevailing range. The current 2024-2026 market sets three operator tiers:

Single-DVM / small-practice tier

Multiple range: 2.32x – 2.85x SDE / 5x – 7x EBITDA for $200K-$500K SDE practices.

Typical seller: solo practitioner or 2-DVM practice, owner working full-time, $50K-$1M in EBITDA after compensation normalization. Buyer pool: regional consolidators looking for tuck-ins, individual veterinarian buyers (often with SBA-financing), and the smaller PE-backed platforms looking for footprint extension. Premium end of the range requires strong local brand, transferable staff, multi-DVM (not solo) operations, and assumable lease or owned real estate. Source: Peak Business Valuation: vet clinic multiples | Transitions Elite: vet practice valuation.

Multi-practice / mid-market tier

Multiple range: 8x – 11.5x EBITDA for $1M–$3M EBITDA operations. Related: our walkthrough on private equity funds 2026.

Typical seller: 3-15 location MSO, professional management in place, mixed general + specialty exposure. Buyer pool: all the institutional platforms profiled above (Mars / Ethos / PetVet / Mission / Thrive / VetCor / Heartland) plus growth-stage PE underwriting new platforms. Premium positioning factors: multi-state footprint, specialty / ER exposure, OEM-equivalent equipment and digital systems (CT, MRI for premium specialty), low DVM turnover, and a transferable medical director / regional management bench. Source: First Page Sage: veterinary practice EBITDA multiples | Transitions Elite: vet practice EBITDA multiples.

Platform-eligible tier

Multiple range: 11x – 13x+ EBITDA for true platform-quality operators ($3M+ EBITDA). See also: private equity vs hedge fund 2026.

Typical seller: $3M+ EBITDA, 10+ locations, multi-state, mix of general and specialty / ER, professional CFO/CEO, strong DVM retention, transferable brand and operating systems. Buyer pool: middle-market and upper-middle-market PE looking for a new platform investment, plus the existing consolidators when they target platform-level rather than tuck-in deals. Industry-data sources commonly cite 11x-13x for this tier and note “12x-15x” for the strongest specialty-heavy platforms; the Q1 2025 published range (per SovDoc and Transitions Elite) was 6x-16x adjusted EBITDA depending on size, staff stability, and location.

Real estate

Owned real estate is generally valued separately at a cap rate of approximately 6.5%-8% for general-practice properties and somewhat lower (5.5%-7%) for purpose-built specialty / 24-hour hospitals with high traffic and infrastructure. Sale-leaseback to a healthcare REIT or to the buyer’s affiliated property vehicle is the standard structure; owner-rolled real estate is common when the buyer wants to preserve owner alignment.

Acquisition criteria: what veterinary platforms look for

• DVM retention and pipeline. The DVM shortage is structural. Buyers underwrite the senior-DVM bench, the apprenticeship/relief-DVM pipeline, and the medical director succession plan, not just the trailing-twelve EBITDA.
• Multi-DVM (not solo) operations. Solo-DVM practices are highly key-person-dependent; the value premium for going from 1 DVM to 3+ DVMs is material.
• Specialty / ER exposure. Even 20-30% of revenue in specialty or ER services materially compresses multiples upward because of higher acuity, lower price-shopping, and 24/7 utilization.
• Geographic density and multi-state footprint. Regional concentration past a certain point can trigger FTC scrutiny (see the JAB divestitures), so platforms increasingly prefer multi-state spread.
• Recurring wellness program enrollment. Wellness plans (Banfield-style subscription programs, Optimum Wellness Plans, ThriveMore-style tiered subscriptions) create structural recurring revenue and compress multiples upward.
• Equipment and digital infrastructure. Modern in-house imaging (digital radiography minimum; CT and MRI for specialty tier), in-house pathology, and integrated PMS (AVImark, Cornerstone, ezyVet, Pulse, Provet Cloud) with monthly close inside 15 days are floor expectations for institutional buyers.
• Real estate quality. Owned real estate with appropriate zoning (or assumable long-term leases of 15+ years) without related-party landlord opacity.

What this means for veterinary owners considering an exit

Three operator-tier strategies, in order of typical exit value:

1. If you are a single-DVM or 2-DVM practice owner, your realistic exit is 2.32x-2.85x SDE plus real estate (separately, at cap-rate value). Pre-sale prep over 18-24 months focused on hiring a second or third DVM, building a wellness-plan recurring-revenue book, modernizing equipment and PMS, and cleaning up real estate and lease documentation can move you toward the upper end of the SDE range or unlock institutional-buyer interest at EBITDA multiples.
2. If you are a 3-15 practice MSO, your realistic exit is 8x-11.5x EBITDA. The key levers between 8x and 11.5x are specialty / ER mix, multi-state footprint, DVM retention and bench depth, and customer-concentration scrubbing. Build a 12-month pre-sale plan with a sell-side QofE provider and a real M&A advisor; the vet M&A market is sufficiently active and price-sensitive that broker-led processes (without a real advisor) are leaving 1x-2x of EBITDA on the table.
3. If you are platform-eligible ($3M+ EBITDA, 10+ locations, multi-state, specialty/ER exposure), your realistic exit is 11x-13x+ EBITDA from middle-market PE, with rollover equity for a meaningful second exit in 3-5 years. With NVA having been absorbed into Ethos in July 2025, with Mission Pet Health newly formed, and with JAB / Ethos preparing for separate IPOs, the buyer landscape for platform-level deals is in active reshuffling. Sponsor fit, not headline multiple, is the most important variable.

CT Acquisitions runs a buy-side advisory; we represent the buyer universe profiled above. See the How to Sell a Veterinary Practice and How to Sell a Veterinary Specialty Hospital guides for the sell-side process detail, and the Owner’s Exit Checklist for the 18-24 month preparation framework.

Limitations of this analysis

• Mars Veterinary Health does not publish financials. Mars is a privately-held, family-owned conglomerate; revenue and EBITDA for Mars Petcare / Mars Veterinary Health are not separately reported. Public scale figures (3,000 hospitals worldwide) come from press accounts and trade press, not audited filings.
• Ethos / NVA integration is in active flux. The July 31, 2025 Ethos acquisition of NVA is recent enough that the combined entity’s location count, acquisition cadence, and FTC divestiture schedule are evolving. We list the pre-acquisition standalone scale figures (145 Ethos specialty + 700 NVA general) and disclose the integration is in progress.
• Thrive Pet Healthcare is in financial distress. We include Thrive because it is structurally still a U.S. consolidator with hundreds of hospitals, but the S&P CCC+ rating and the “likely unsustainable” capital-structure framing mean that Thrive’s near-term capacity to close new add-ons is materially constrained. Owners evaluating a sale to Thrive should explicitly weigh financing-certainty risk.
• Most platform-level financial terms are private. The Mars / VCA $9.1B and JAB / Ethos $1.65B figures are exceptions because they involved publicly-listed targets or court-disclosed FTC orders. Most other vet transactions disclose neither EV nor multiple. The 11x-13x+ platform-tier range reflects industry-data sources (First Page Sage, SovDoc, Transitions Elite) and CT Acquisitions’ active-engagement underwriting; it does not reflect a specific named transaction.
• Industry-data tier multiples are aggregated. The cited ranges blend general-practice and specialty practices, geographic differences, and capital-mix differences. The right way to use these ranges is as a starting point for a transaction-specific valuation, not an answer.
• Subscription-gated figures are labeled. Where we cite IBISWorld market sizing or Grand View Research full-report figures, the underlying report is paywalled; we cite the publisher.
• FTC scrutiny is structural. The JAB divestiture orders mean that future large-scale vet roll-up transactions will face an active FTC review. Owners selling to large platforms should expect a non-trivial regulatory timeline (45-90 days additional close timing in many cases).
• We exclude pet retail and pet insurance from this tracker. Petco, PetSmart, Chewy, Lemonade Pet, Trupanion, etc. are different M&A categories and would dilute the focus on hospital-level veterinary services.

Future updates and methodology notes

Refresh cadence: quarterly. The next scheduled refresh is August 24, 2026. Specific 2026 refresh triggers we are watching:

• JAB / Ethos IPO timing. JAB’s stated intent to take its veterinary platforms public over the next 2-3 years is the single largest disclosure event coming. Any S-1 filing will materially expand visibility into vet platform economics.
• Thrive Pet Healthcare restructuring outcome. The S&P “likely unsustainable” framing and the March 2025 liability management exercise leave Thrive as a watch item for distressed M&A, secondary sponsor transition, or further restructuring.
• Mission Pet Health post-integration cadence. The 2024 SVP + MVP combination is large enough that the combined acquisition cadence in 2026 will reset benchmark expectations for the growth tier.
• FTC enforcement evolution. Multiple vet roll-up deals are under varying levels of FTC review; any new prior-approval order would change platform acquisition behavior.

How to flag corrections: Every named platform on this page is sourced to a primary press release, FTC filing, SEC filing, or sponsor portfolio page. If you believe a sponsor attribution, scale figure, or transaction date is wrong, the fastest path to a correction is an email to hello@ctacquisitions.com with the primary source (press release URL, FTC matter, or SEC filing) that contradicts what we have published. We re-verify and patch within 5 business days.

What this tracker does not do: We do not publish private-deal pricing without primary-source attribution, we do not name buyers in active CT engagements, and we do not produce projections about future multiples or platform behavior.

Related research

• Private Equity in Dermatology 2026 — the companion tracker for the physician-MSO side of healthcare consolidation.
• 2026 Dental DSO PE Roll-Up Tracker — the dental analog covering 21 active U.S. dental DSO platforms.
• How to Sell a Veterinary Practice — the sell-side process guide for general-practice owners.
• How to Sell a Veterinary Specialty Hospital — the sell-side process guide for specialty / ER operators.
• Lower Middle Market Buyer Mandate Report 2026 — 100+ active U.S. acquirers profiled across all sectors.
• Owner’s Exit Checklist — 24-item pre-sale preparation framework.

Sources and references

Every named platform, sponsor, and scale figure on this page is sourced to a primary press release, FTC filing, SEC filing, or sponsor portfolio page. Industry-data tier (multiples, market size, fragmentation) draws on the named industry research publishers. Subscription-gated figures are labeled in body where used.

• PR Newswire: Mars completes VCA acquisition (Sept 2017) — $9.1B Mars / VCA transaction primary source
• VCA Animal Hospitals press center: Mars acquisition — platform-side primary source
• Veterinary Practice News: Mars completes VCA acquisition — trade press confirmation of close
• Fortune: Mars as the biggest vet provider — 2024 scale and growth recap
• Ethos Veterinary Health: NVA and Ethos announcement (2025) — July 31, 2025 NVA acquisition primary source
• PE Hub: JAB / NVA acquires Ethos $1.65B — original Ethos acquisition deal source
• AVMA: NVA splits into two businesses — 2024 corporate-structure split announcement
• FTC: Second action against JAB Consumer Partners (June 2022) — regulatory scrutiny primary source
• FTC Matter 2110140: JAB / NVA / SAGE — case docket primary source
• AVMA News on FTC actions — trade press FTC summary
• L Catterton press: KKR acquires PetVet — PetVet sponsor history
• GlobeNewswire: SVP + MVP merger announcement — Mission Pet Health formation primary source
• Mission Pet Health: merger announcement — platform-side primary source
• VetCor company site — platform scale and thesis
• Heartland Veterinary Partners company site — platform scale and thesis
• Peak Business Valuation: Veterinary Clinic Multiples — SDE / EBITDA benchmark
• First Page Sage: Veterinary Practice EBITDA & Valuation Multiples (2025) — 8x-13x tiered benchmark
• Transitions Elite: Veterinary Practice Valuation — Q1 2025 transaction range data
• SovDoc: How to Value a Veterinary Practice — comprehensive 2025 framework
• Mordor Intelligence: Veterinary Services Market — fragmentation (51% independent) and consolidation share
• IBISWorld: Veterinary Services in the US — industry sizing reference (subscription-gated)
• Axial: EBITDA Multiples by Industry — LMM benchmark synthesis
• Private Equity Stakeholder Project: Antitrust enforcement in veterinary medicine — consolidation policy analysis
• CT Acquisitions Roll-Up Tracker series — companion methodology across dental DSO, plumbing, roofing, pest control, manufacturing, auto repair, auto body.

Last verified: May 24, 2026. Next refresh: quarterly (target 2026-08-24).

Disclaimer: This tracker is general market intelligence, not investment, legal, or tax advice. Multiples and outcomes by operator tier are illustrative; actuals vary with deal structure, geography, and buyer fit. CT Acquisitions is a buy-side advisor; we represent acquirers and may have active engagements with platforms profiled here.